| Citation: |
ZHAI Shupeng, JIA Hang, ZHOU Guoping. The relationships of serum α-synuclein, microtubule-associated protein 1 light chain 3, apolipoprotein A1 with cognitive function and disease progression in Parkinson's disease[J]. Journal of Clinical Medicine in Practice, 2023, 27(22): 62-66. DOI: 10.7619/jcmp.20232668
|
To detect the expressions of α-synuclein, microtubule-associated protein 1 light chain 3 (LC3) and apolipoprotein A1 (Apo A1) in serum of patients with Parkinson's disease (PD), and their correlations with cognitive function (CI) and disease progression.
Ninety-six PD patients were selected as research group; another 90 healthy subjects were selected as control group. The patients were divided into CI group (42 cases) and cognitively normal group (54 cases) according to the Montreal Cognitive Assessment Scale (MoCA) score. PD patients were divided into stages Ⅰ, Ⅱ, Ⅲ, Ⅳ and Ⅴ according to the Hoehn-Yahr (H-Y) Staging Scale, patients in stage Ⅰ to Ⅱ were included in early PD group (57 cases), and those with stage Ⅲ to Ⅴ were in middle and late PD group (39 cases). The levels of serum α-synuclein and LC3, PD and Apo A1 patients were determined. The correlations of α-synuclein, LC3, Apo A1 with H-Y staging were analyzed. Logistic regression analysis was applied to screen the influencing factors of occurrence of CI in PD patients.
Compared with the control group, the level of α-synuclein in the research group increased, and the levels of LC3 and Apo A1 decreased (P < 0.05); the level of α-synuclein in the early PD group was lower than that in the middle and late PD group, and the levels of LC3 and Apo A1 were higher than those in the middle and late PD group (P < 0.05); serum α-synuclein level was positively correlated with H-Y staging (P < 0.05). The area under the curve (AUC) of their combination to predict the occurrence of cognitive impairment in PD patients was 0.925, which was greater than prediction by α-synuclein, LC3, and Apo A1 alone (P < 0.05); α-synuclein, LC3, Apo A1, and history of hypertension were the influencing factors of CI in PD patients (P < 0.05).
α-synuclein is highly expressed in the serum of patients with PD complicated with cognitive impairment, while the expression of LC3 and Apo A1 are low. The three are closely related to PD cognitive function and disease progression.
| [1] |
周智君, 夏建国, 陈锦华, 等. 扩散峰度成像与扩散张量成像诊断帕金森病患者脑白质损伤的比较研究[J]. 实用临床医药杂志, 2022, 26(11): 22-27. doi: 10.7619/jcmp.20220888
|
| [2] |
施艳, 王圆圆, 刘学东, 等. 帕金森病共患失眠患者应用睡眠限制疗法的效果[J]. 实用临床医药杂志, 2021, 25(23): 49-52. doi: 10.7619/jcmp.20214395
|
| [3] |
DOIRON M, LANGLOIS M, DUPRÉ N, et al. The influence of vascular risk factors on cognitive function in early Parkinson's disease[J]. Int J Geriatr Psychiatry, 2018, 33(2): 288-297. doi: 10.1002/gps.4735
|
| [4] |
SEKIYA H, TSUJI A, HASHIMOTO Y, et al. Discrepancy between distribution of alpha-synuclein oligomers and Lewy-related pathology in Parkinson's disease[J]. Acta Neuropathol Commun, 2022, 10(1): 133. doi: 10.1186/s40478-022-01440-6
|
| [5] |
刘汝兰, 毛汉潇, 何渊民, 等. ROS调控细胞自噬在UVA致人皮肤成纤维细胞凋亡中的作用[J]. 中国皮肤性病学杂志, 2023, 37(1): 10-16. https://www.cnki.com.cn/Article/CJFDTOTAL-ZBFX202301003.htm
|
| [6] |
于鸿远, 何景华, 刘双, 等. 帕金森病患者的血脂水平及其相关性[J]. 中国康复理论与实践, 2019, 25(3): 352-356. https://www.cnki.com.cn/Article/CJFDTOTAL-ZKLS201903023.htm
|
| [7] |
DUAN M, CHEN H N, YIN L J, et al. Mitochondrial apolipoprotein A-I binding protein alleviates atherosclerosis by regulating mitophagy and macrophage polarization[J]. Cell Commun Signal, 2022, 20(1): 60. doi: 10.1186/s12964-022-00858-8
|
| [8] |
SCHRAG A. Testing the MDS clinical diagnostic criteria for Parkinson's disease[J]. Mov Disord, 2018, 33(10): 1518-1520. doi: 10.1002/mds.27543
|
| [9] |
张东亚, 杨改清, 张晓艺, 等. 血清胱抑素C、同型半胱氨酸、叶酸、血尿酸水平与帕金森病认知功能障碍的相关性[J]. 中国老年学杂志, 2017, 37(3): 633-635. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLXZ201703049.htm
|
| [10] |
GOETZ C G, POEWE W, RASCOL O, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations[J]. Mov Disord, 2004, 19(9): 1020-1028.
|
| [11] |
高焱, 郭晓贤, 康静. 血清Hcy、CysC、UA及EGF水平与帕金森病合并认知功能障碍的关系[J]. 临床医学研究与实践, 2020, 5(27): 125-127. https://www.cnki.com.cn/Article/CJFDTOTAL-YLYS202027052.htm
|
| [12] |
刘璇, 雷晶, 马建华, 等. 血清胱抑素C、血脂与帕金森病合并认知障碍的相关研究[J]. 神经损伤与功能重建, 2021, 16(4): 237-239. https://www.cnki.com.cn/Article/CJFDTOTAL-GWKF202104016.htm
|
| [13] |
TOFARIS G K. Initiation and progression of α-synuclein pathology in Parkinson's disease[J]. Cell Mol Life Sci, 2022, 79(4): 210.
|
| [14] |
蔡卫卫, 许晓辉, 刘超, 等. 血清α-突触核蛋白及类胰岛素1号增长因子水平与帕金森病患者认知功能的相关性分析[J]. 中国实用神经疾病杂志, 2021, 24(12): 1048-1053. https://www.cnki.com.cn/Article/CJFDTOTAL-HNSJ202112006.htm
|
| [15] |
明敬峰, 魏红玉, 张永进, 等. 帕金森病患者血浆α-synuclein、LC3、CacyBP/SIP水平与临床症状的相关性[J]. 中国老年学杂志, 2022, 42(6): 1420-1423. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLXZ202206042.htm
|
| [16] |
SHEN Y N, ZHANG Y, DU J Y, et al. CXCR5 down-regulation alleviates cognitive dysfunction in a mouse model of sepsis-associated encephalopathy: potential role of microglial autophagy and the p38MAPK/NF-κB/STAT3 signaling pathway[J]. J Neuroinflammation, 2021, 18(1): 246.
|
| [17] |
孙晓燕, 汤海燕. 不同亚型帕金森病患者血清尿酸、载脂蛋白A1及谷胱甘肽水平对比[J]. 中国老年学杂志, 2022, 42(12): 2963-2965. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLXZ202212033.htm
|
| [18] |
LI L, LIU M S, LI G Q, et al. Relationship between apolipoprotein superfamily and parkinson's disease[J]. Chin Med J, 2017, 130(21): 2616-2623.
|
| [19] |
孙皓晨, 娄凡, 李思颖, 等. 帕金森病认知功能障碍与脑血管病危险因素的相关研究进展[J]. 中国神经免疫学和神经病学杂志, 2018, 25(5): 371-374. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSMB201805016.htm
|
© 2020 《实用临床医药杂志》编辑部
Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807
Supported by:
Beijing Renhe Information Technology Co., Ltd.
苏公网安备 32100302010246号
DownLoad: